Placebo + Methotrexate

DRUG2 trials

Sponsors

Pfizer, Tanabe Pharma Corporation

Conditions

Rheumatoid Arthritis

Phase 2

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

CompletedNCT00976599

PfizerRheumatoid Arthritis

Start: 2009-11-30End: 2011-07-31Updated: 2013-01-09

Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis

CompletedNCT01143337

Tanabe Pharma CorporationRheumatoid Arthritis

Start: 2010-06-30End: 2012-03-31Updated: 2026-01-06

Related Papers

Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib

Arthritis Research & Therapy2024-08-273 citations

Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.

2024-07-032 citations

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.

2024-05-025 citations

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials

Arthritis Research & Therapy2023-11-027 citations

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.

2023-03-1781 citations

Fracture in clinical studies of tofacitinib in rheumatoid arthritis.

2022-12-279 citations

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.

2022-12-175 citations

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.

2022-12-05100 citations

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.

2021-12-067 citations

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

RMD Open2020-10-01169 citations

Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.

2020-08-2013 citations

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.

2019-03-2817 citations

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

2017-01-31279 citations

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.

2014-11-14213 citations